Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06285188
Other study ID # APHP221174
Secondary ID 2023-A01398-37
Status Not yet recruiting
Phase
First received
Last updated
Start date March 2024
Est. completion date March 2026

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Alexandra SERRIS, MD, PhD
Phone +33 6 68 80 24 92
Email alexandra.serris@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.


Description:

Invasive fungal diseases (IFD) still cause substantial morbidity and mortality. New therapeutic approaches are therefore urgently needed, notably for patients not responding to conventional antifungal treatment. One strategy to prevent treatment failure is to improve the immune functions of immunocompromised hosts. Indeed, antifungals therapeutic efficacy is limited without the help of host immune reactivity (Stevens et al., 2000). As several studies have suggested that IFD are associated with an impaired Th1 host immune response, various cytokines have been evaluated in experimental and human fungal infections. In particular, adjunction of recombinant IFNγ has been proposed as a treatment option in patients with poor prognosis IFD with partial success. More recently, it has been shown that, when T cells are exposed to persistent antigens and/or inflammatory signals due to inefficient control of persisting infections, or in the context of tumors, a deterioration of their functions is observed, a state called "exhaustion". Molecular pathways involved in exhaustion have been partially deciphered, highlighting the importance of molecules called immune checkpoint such as PD-1 or CTLA-4. Furthermore, it was shown that blockade of these molecules can reverse this dysfunctional state. Immune checkpoint inhibitors (such as anti-PD1 antibodies) have become major weapons in oncology. In infectious diseases, and more particularly IFDs, data are much more limited. In animal models of several IFD, such as aspergillosis, cryptococcosis and histoplasmosis, repetitive administration of anti-PD-1 monoclonal antibodies significantly improved fungal clearance and survival of lethally infected animals. In humans, three case-reports, including one published by our team, have reported the efficacy of anti-PD-1 therapy combined with IFN-γ in the treatment of refractory IFDs. Therefore, by reversing T cell exhaustion, immune checkpoint blockade represents a therapeutic perspective for IFD treatment. The use of immune checkpoint inhibitors may, however, entail severe, notably autoimmune off-target adverse effects and should be carefully balanced and monitored. The development of tools allowing identification of patients who could benefit from immunotherapy is of particular importance as well as assessment of the optimal timing of these innovative treatments. As such, a better understanding of the host immune response is one of the major approaches to developing new or improved antifungal strategies to control IFDs. Longitudinal data regarding the evolution of exhaustion markers expression in T cells of patients treated for an IFD are lacking. The goal is to better characterize the adaptative immune response directed against molds, notably immune checkpoint expression, in order to identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy. For this purpose, the investigators will include adult patients with mold IFD either at diagnosis or refractory to conventional therapy. They will measure activation and exhaustion markers on circulating T cells and monocytes by flow cytometry at three timepoints (enrollment, day 14 and week 6). Moreover, for patients with invasive aspergillosis or mucormycosis, they will evaluate the capacity of specific T cells to produce Th1, Th2 and Th 17 cytokines and to proliferate after specific antigenic stimulation, in the absence and in the presence of an anti-PD1 antibody in vitro (4 colors FLUOROSPOT) at two timepoint (enrollment and week 6). These data will provide a longitudinal assessment of the anti-fungal immune response. They will be correlated with the underlying diseases of the patients, the type of mold infection (aspergillosis, mucormycosis, fusariosis or scedosporiosis), the treatment received and the outcome. These results should help to better identify patients who could benefit from adjunctive anti PD-1 treatment and the optimal timing for such treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date March 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - Mold invasive fungal infection: Aspergillus, Mucorales, Fusarium, Scedosporium - Proven or probable according to 2019 EORTC/MGS criteria modified by the adjunction of diabetes mellitus in the host criteria and Mucorales PCR in the microbiological criteria - Within 14 days of IFD diagnosis or at a refractory state defined by the 2009 MGS/EORT failure criteria (clinical, radiological, or microbiological failure) of a first-line antifungal treatment leading to a change of therapy by the attending physician of the patient Exclusion Criteria: - Lymphocyte count < 0.5 G/L - Bacterial infection in the last 14 days - Previous treatment with anti-PD1 antibodies

Study Design


Locations

Country Name City State
France Hôpital Necker Enfants Malades Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immune checkpoint expression on T cells percentage of circulating T cells expressing immune checkpoint molecules as well as the intracellular transcription factor TCF1 and mean fluorescence intensity (MFI) of this expression in each cell sub-population Day 0, day 14, week 6
Secondary Aspergillus/Mucorales FLUOROSPOT Qualitative and quantitative measure of specific T cells IFN-?/IL-2/IL-5/IL-17 production by FLUOROSPOT after antigenic stimulation in absence and presence of an anti-PD1 antibody in patients with invasive aspergillosis or mucormycosis Day 0, week 6
Secondary T cell proliferation T cell proliferation test after antigenic stimulation Day 0, week 6
Secondary Immune checkpoint expression on monocytes Percentage of circulating monocytes expressing immune checkpoint molecules Day 0, day 14, week 6
See also
  Status Clinical Trial Phase
Recruiting NCT05116059 - To Evaluate the Efficacy and Safety of ABCD in the Treatment of IFD
Completed NCT01916057 - Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis N/A
Completed NCT03262584 - Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
Recruiting NCT04368559 - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 3
Recruiting NCT01731353 - FungiScope - A Global Emerging Fungal Infection Registry
Recruiting NCT05569824 - LFD of Aspergillus Antigen in Paediatrics
Completed NCT03577509 - Single Dose Escalations Study of Amphotericin B Colloidal Dispersion In Healthy Subjects in China Phase 1
Recruiting NCT03774316 - De-escalation - Antifungal Treatment Immunocompromised Patients
Recruiting NCT05630976 - Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi Phase 4
Not yet recruiting NCT06376201 - A Clinical Study on the Efficacy and Safety of ABCD in the Treatment of Patients With Invasive Fungal Disease Phase 4
Completed NCT01259713 - Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia Phase 3
Recruiting NCT01135589 - Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation Phase 4